Investor Presentaiton

3 De-risked Business Model With Diverse Sources of Revenue Presence in niche Specialty businesses that have high barriers to entry Diverse end-use industry segmentation in Life Science Ingredients with focus on Pharmaceutical and Agrochemical industries Presence across geographic locations enables the company to capture different market segments Diverse Segments FY19 Revenue Split¹ DDDS 2% Life Sciences Chemicals Specialty Pharmaceuticals 31% I 23% Nutritional Products 5% Specialty Intermediates 11% Generics 12% CDMO 16% Diverse revenue base with substantial revenue contribution from Specialty Pharma, CDMO, Generics, Life Science Chemicals and Specialty Intermediates and Nutritional Products businesses 100% Rs 9,111 Cr Diverse Products Broad Customer Base Broad Geographical Base FY19 Revenue Split FY19 Revenue Split Rest of the Products 59% Top 10 Products | 41% I Rest of the Customers 80% Top 10 products account for 41% of FY19 Revenue FY19 Revenue Split Top 10 Customers 20% China and ROW 8% Europe & Japan 14% India 27% USA & Canada 51% Diversified customer base with top 10 customers accounting for only 20% of the revenue Broad geographic base with North America and India being the major markets JUBILANT 1. IBP business, earlier presented under segment 'Others' has from Q2'FY20 onwards been reclassified under 'Pharmaceuticals' segment within 'Generics' subsegment PHARMA

View entire presentation